Congratulations Mulki Mehari, Joshua Bernstock, UCSF Neurosurgery, and Brigham and Women's Neurosurgery for their work demonstrating a survival benefit associated with the neurophysiological drug Gabapentin in newly diagnosed #Glioblastoma, #cancerneuroscience. nature.com/articles/s4146…

This important study included a large annotated dataset and biomarker analysis at UCSF Health and MGB with patients receiving a median dose of 495 mg ([IQR] = 300–900) for a median period of 180 days (IQR = 59.5–614.0), setting the stage for future clinical trials.

Congratulations to UCSF School of Medicine Mulki Mehari for publishing science.org/doi/epdf/10.11…. Despite the goal of maximizing enrollment of brain cancer patients in clinical trials, many studies fail to meet recruitment targets.

This multicenter study developed and externally validated machine learning models to assess the interactive effects of oncologic variables on clinical trial enrollment, identifying key predictors across patient populations.

To facilitate the evaluation of model predictive performance in additional settings and cohorts, we created an open-access tool GPREDICT, which predicts enrollment and provides suggestions for targeted interventions to increase accrual probability mmehari2025.github.io/glioma-trial-p…

New in Science Advances, Mulki Mehari, Annette Molinaro, PhD, Shawn Hervey-Jumper, and their colleagues present a new AI-based clinical trial enrollment tool that provides recommendations for personalized for each patient’s circumstances: science.org/doi/10.1126/sc… UCSF Helen Diller Family Comprehensive Cancer Ctr